Kenny Walter is an editor with HCPLive. Prior to joining MJH Life Sciences in 2019, he worked as a digital reporter covering nanotechnology, life sciences, material science and more with R&D Magazine. He graduated with a degree in journalism from Temple University in 2008 and began his career as a local reporter for a chain of weekly newspapers based on the Jersey shore. When not working, he enjoys going to the beach and enjoying the shore in the summer and watching North Carolina Tar Heel basketball in the winter.
Rheumatoid arthritis patients with probably major depressive disorder or generalized anxiety disorder were more likely to suffer from worse fatigue and pain.
A team, led by Gustavo Citera, Department of Rheumatology, Psychophysical Rehabilitation Institute, assessed both probable major depressive disorder (pMDD) and probable generalized anxiety disorder (pGAD) in rheumatoid arthritis patients treated with tofacitinib, an oral JAK inhibitor, and efficacy by baseline pMDD/pGAD status.
The investigators pooled data from patients receiving tofacitinib , ADA, or placebo from 5 phase 3 and 1 phase 3B/4 trials. The demographics and baseline characteristics was reported by baseline pMDD/pGAD (SF-36 MCS ≤38, presence; >38, absence).
The investigators also estimated month 3,6,9 and 12 SF-36 MCS change from baseline and percentage with pMDD and pGAD reported.
They also compared efficacy outcomes at months 3, 6, and 12 of tofacitinib treated patients by baseline pMDD and pGAD.
The investigators found baseline major depressive disorder or generalized anxiety disorder in 44.5% of patients treated with tofacitinib 5mg BID, 39,8% of individuals treated with tofacitinib 10mg BID, 45.4% of patients treated with ADA 40mg Q2W, and 39.1% of patients in the placebo arm.
The team also found patients likely suffering from either psychiatric disorder had higher baseline CRP and worse disability, fatigue, pain, and sleep when compared to patients without the likelihood of either major depressive disorder or generalized anxiety disorder.
The percentage of patients with baseline pMDD or pGAD who continued to have these disorders reduced over time. The percentage of these patients was also generally lower for individuals treated with tofacitinib when compared to patients in the placebo or ADA groups.
They also found regardless of baseline status, efficacy was similar for tofacitinib 5mg BID and 10mg BID.
“[Approximately] 40% of RA patients had baseline pMDD/pGAD. SF-36 MCS improvements were greater for tofacitinib vs placebo/ADA,” the authors wrote. “With tofacitinib, percentage of patients with SF-36 MCS ≤38 reduced by ~60% at month 12. Tofacitinib efficacy was similar in patients with/without baseline pMDD/pGAD. Limitations include using SF-36 MCS to identify probable rather than confirmed MDD or GAD. Future research using gold standard psychiatric interviews to validate use of SF-36 MCS ≤38 is needed.”
Tofacitinib has also been tested in another study presented during the virtual EULAR meeting for patients with psoriatic arthritis.
In a post hoc analysis, investigators from Brazil compared DAPSA LDA with MDA, as well as DAPSA remission with very low disease activity and DAS28-3 (CRP) remission, in patients with psoriatic arthritis receiving tofacitinib.
The investigators found that at month 3, older patients with higher baseline SJC66, TJC68, PtGA VAS, HAQ-DI, LEI and Pain VAS, were significantly (P <0.05) more likely to have higher DAPSA.
They also found that DAPSA LDA, MDA, remission (DAPSA and DAS28-3[CRP]) and very low disease activity rates generally increased from month 1 to month 6 for patients receiving tofacitinib 5 mg BID.
At month 6, the patients receiving the study drug achieved MDA and all patients received very low disease activity and were also in DAPSA remission or LDA.
The study, “Tofacitinib in Patients with Rheumatoid Arthritis and Indicative of Depression and/or Anxiety: A Post Hoc Analysis of Phase 3 and Phase 3B/4 Clinical Trials,” was published online by EULAR.